Mural Oncology plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MURA research report →
Price Chart
About the company
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12.
- CEO
- Caroline J. Loew
- IPO
- 2023
- Employees
- 116
- HQ
- Dublin, IE
Get TickerSpark's AI analysis on MURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.38M
- P/E
- -0.68
- Fwd P/E
- 6.00
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 0.64
- EV/EBITDA
- 0.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -90.71%
- ROIC
- -60.14%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-3,512,000-36.8%
- Op Income
- $-138,262,000
- Net Income
- $-128,514,000+38.0%
- EPS
- $-7.58+39.0%
- OCF Growth
- +33.8%
- FCF Growth
- +34.9%
- 52W High
- $4.74
- 52W Low
- $0.95
- 50D MA
- $2.08
- 200D MA
- $2.37
- Beta
- 2.96
- RSI (14)
- 40
- Avg Volume
- 170.82K
No earnings-call transcripts are available for MURA yet.
- Free Float
- 70.0%
- Shares Outstanding
- 17.34M
- Float Shares
- 12.14M
of shares held by institutions
68 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 342.63K | ▼ 741.33K |
| Sonic Gp LLC | 166.98K | 0 |
| Lindbrook Capital, LLC | 1 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 5, 25 | Hickey Benjamin | sell | 15,021 |
| Dec 5, 25 | Hickey Benjamin | sell | 8,637 |
| Dec 5, 25 | Hickey Benjamin | sell | 8,462 |
| Dec 5, 25 | Loew Caroline | sell | 293,059 |
| Dec 5, 25 | Loew Caroline | sell | 379,690 |
| Dec 5, 25 | Loew Caroline | sell | 134,225 |
| Dec 5, 25 | Loew Caroline | sell | 90,025 |
| Dec 5, 25 | Cuss Francis M | sell | 8,637 |
| Dec 5, 25 | Cuss Francis M | sell | 8,462 |
| Dec 5, 25 | Cuss Francis M | sell | 15,021 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MURA coverage
Recent articles, reports, and earnings notes.
No research on MURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MURA report →Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus PT from Brokerages
defenseworld.net · Jan 14
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages
defenseworld.net · Dec 20
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
globenewswire.com · Dec 5
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
globenewswire.com · Dec 5
Mural Oncology Announces Sanction of the Scheme by the High Court
globenewswire.com · Dec 3
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
globenewswire.com · Nov 26
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
globenewswire.com · Oct 24
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
globenewswire.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.